Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases detection of new cognitive conditions/concerns in older adults, according to a study published online June 12 in Frontiers in Medicine.
Douglas W. Scharre, M.D., from The Ohio State University Wexner Medical Center in Columbus, and colleagues compared PCP visits with and without using the self-administered SAGE to determine differences in identification rates of new cognitive disorders. The analysis included 300 patients (aged 65 to 89 years) without diagnosed cognitive disorders completing a nonacute office visit.
The researchers found that when SAGE was utilized, the PCP documented the detection of new cognitive conditions/concerns six times as often (9 versus 1.5 percent). For those with cognitively impaired SAGE scores, the detection rate was nearly fourfold higher, while patients having impaired SAGE score and informant concerns were 15-fold as likely to have new cognitive conditions/concerns documented.
"PCPs felt SAGE influenced their decision to further evaluate for cognitive impairment, led to more confidence regarding the presence or absence of cognitive impairment, and 86 percent would recommend its use to colleagues," the authors write.
The Ohio State University holds the copyright for the SAGE test. One author disclosed ties to BrainTest.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-03 01:15
Read more
- PSMA-PET Provides Additional Risk Stratification in High-Risk Prostate Cancer
- PREVENT Equations Classify 15 Million at Elevated Risk for Heart Failure
- Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
- Cannabidiol Safe, May Lower Anxiety in Advanced Breast Cancer
- Children With Primary Ciliary Dyskinesia Likely to Have Asthma
- FDA Calls for Better Accuracy of Pulse Oximeters in People of Color
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions